Molecular Insights into Proteinopathies: Increased Scope from Neurodegeneration to other Pathologies of the Brain investigates the molecular events that lead to various diseases. The book is divided into four parts, the first of which delves into protein aggregation across a range of diseases, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, and neuropsychiatric diseases. It then moves on to discuss signaling pathways and biomarkers of disease, including oxidative stress, mitochondrial decline, and dysregulated molecular pathways. The third part explores small molecules as modulators of key processes in the pathogenesis of proteinopathies, including antioxidants, polyphenol compounds, metal chelators, and repurposed drugs that modulate proteinopathies.
The final section considers biophysical methods, molecular dynamics, and machine learning approaches in the study of these aspects. The book provides a detailed overview of protein dysfunction and its implications for health and disease, aiding understanding of protein condensates and aggregates, protein misfolding, co-chaperoning and toxicity of pre-amyloid aggregates. By understanding the fundamental properties underlying these, the book paves the way for investigating how proteinopathies could be treated.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. List of contributors - p. xi 7. Preface - p. xv 8. Acknowledgments - p. xvii 9. Part 1: Protein aggregation in different proteinopathies - p. P1 10. Chapter 1. Amyloid-pore hypothesis: prefibrillar oligomers interactions with membranes; a generic cause of neurodegeneration? - p. 3 11. Chapter 2. In vivo molecular brain imaging of metabolic dysfunction and protein accumulation in neurodegenerative diseases - p. 21 12. Chapter 3. Proteins that show aggregation in the brains of patients with schizophrenia and other chronic mental illnesses - p. 37 13. Chapter 4. Protein aggregation in progressive myoclonus epilepsies: focus on progressive myoclonic epilepsy type 1 - p. 83 14. Part 2: Common signaling pathways and biomarkers of proteinopathies - p. P99 15. Chapter 5. Neuroinflammation and neurodegeneration in schizophrenia: potential biomarkers and novel therapeutic strategies - p. 101 16. Chapter 6. Disease-specific glycosylation in the neurodegenerative brain - p. 135 17. Chapter 7. Dysregulated molecular pathways in amyotrophic lateral sclerosis–frontotemporal dementia spectrum disorder - p. 189 18. Chapter 8. New treatments on the horizon for Alzheimer’s and other neurodegenerative diseases - p. 213 19. Part 3: Small molecules as modulators of the key processes in proteinopathies - p. P245 20. Chapter 9. Small molecule modulators of protein aggregation and toxicity: antioxidants and polyphenol compounds - p. 247 21. Chapter 10. Involvement of CB1 and CB2 receptors in neuroprotective effects of cannabinoids - p. 269 22. Chapter 11. Role of autophagy in aging and aging-related neurodegenerative diseases - p. 297 23. Part 4: Contemporary biophysical methods and machine learning - p. P325 24. Chapter 12. Intrinsically unfolded proteins and the role of protein condensation - p. 327 25. Aβ peptides: structure and interaction with membranes as revealed by nuclear magnetic resonance - p. 359 26. Chapter 14. Machine learning in prediction of protein aggregation and/or condensation states - p. 375 27. Index - p. 391
Molecular Insights into Proteinopathies: Increased Scope from Neurodegeneration to other Pathologies of the Brain investigates the molecular events that lead to various diseases. The book is divided into four parts, the first of which delves into protein aggregation across a range of diseases, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, and neuropsychiatric diseases. It then moves on to discuss signaling pathways and biomarkers of disease, including oxidative stress, mitochondrial decline, and dysregulated molecular pathways. The third part explores small molecules as modulators of key processes in the pathogenesis of proteinopathies, including antioxidants, polyphenol compounds, metal chelators, and repurposed drugs that modulate proteinopathies.
The final section considers biophysical methods, molecular dynamics, and machine learning approaches in the study of these aspects. The book provides a detailed overview of protein dysfunction and its implications for health and disease, aiding understanding of protein condensates and aggregates, protein misfolding, co-chaperoning and toxicity of pre-amyloid aggregates. By understanding the fundamental properties underlying these, the book paves the way for investigating how proteinopathies could be treated.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. List of contributors - p. xi 7. Preface - p. xv 8. Acknowledgments - p. xvii 9. Part 1: Protein aggregation in different proteinopathies - p. P1 10. Chapter 1. Amyloid-pore hypothesis: prefibrillar oligomers interactions with membranes; a generic cause of neurodegeneration? - p. 3 11. Chapter 2. In vivo molecular brain imaging of metabolic dysfunction and protein accumulation in neurodegenerative diseases - p. 21 12. Chapter 3. Proteins that show aggregation in the brains of patients with schizophrenia and other chronic mental illnesses - p. 37 13. Chapter 4. Protein aggregation in progressive myoclonus epilepsies: focus on progressive myoclonic epilepsy type 1 - p. 83 14. Part 2: Common signaling pathways and biomarkers of proteinopathies - p. P99 15. Chapter 5. Neuroinflammation and neurodegeneration in schizophrenia: potential biomarkers and novel therapeutic strategies - p. 101 16. Chapter 6. Disease-specific glycosylation in the neurodegenerative brain - p. 135 17. Chapter 7. Dysregulated molecular pathways in amyotrophic lateral sclerosis–frontotemporal dementia spectrum disorder - p. 189 18. Chapter 8. New treatments on the horizon for Alzheimer’s and other neurodegenerative diseases - p. 213 19. Part 3: Small molecules as modulators of the key processes in proteinopathies - p. P245 20. Chapter 9. Small molecule modulators of protein aggregation and toxicity: antioxidants and polyphenol compounds - p. 247 21. Chapter 10. Involvement of CB1 and CB2 receptors in neuroprotective effects of cannabinoids - p. 269 22. Chapter 11. Role of autophagy in aging and aging-related neurodegenerative diseases - p. 297 23. Part 4: Contemporary biophysical methods and machine learning - p. P325 24. Chapter 12. Intrinsically unfolded proteins and the role of protein condensation - p. 327 25. Aβ peptides: structure and interaction with membranes as revealed by nuclear magnetic resonance - p. 359 26. Chapter 14. Machine learning in prediction of protein aggregation and/or condensation states - p. 375 27. Index - p. 391
